Afatinib and palbociclib for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (afatinib and palbociclib) for people with advanced esophageal squamous cell carcinoma that has grown after previous treatment. It is designed for those whose cancer cells have too much of a protein called EGFR.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced esophageal squamous cell carcinoma that cannot be removed by surgery and has spread or come back after treatment.
- Your tumor cells have a lot of EGFR (a protein that helps cancer grow), as shown by a lab test.
- Your cancer has gotten worse after at least one prior treatment.
- You are in generally good health (able to do daily activities with little or no help).
- Your heart, liver, and kidney function are adequate based on blood tests and an ultrasound of your heart.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precision medicine approach for people with advanced esophageal cancer that has stopped responding to immunotherapy. The goal is to find better treatments based on each person's tumor biology.
This trial tests a combination of two drugs (anlotinib and benmelstobart) as a first treatment for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if this combination helps control the cancer.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests a new drug combination for advanced esophageal squamous cell carcinoma that has stopped responding to prior treatment. The goal is to see if the combination can shrink tumors and help patients live longer.
This trial tests a combination of immunotherapy (adebrelimab) and two chemotherapy drugs before surgery for patients with advanced but removable esophageal cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This study tests a new combination of drugs (adebelimab, apatinib, and chemotherapy or chemoradiation) for people with esophageal cancer that has gotten worse after prior immunotherapy. It aims to see if this combination can help when standard first-line treatment stops working.
Hear when a new Esophagus Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.